PL1835937T3 - Kompozycje i sposoby leczenia infekcji wirusowej - Google Patents
Kompozycje i sposoby leczenia infekcji wirusowejInfo
- Publication number
- PL1835937T3 PL1835937T3 PL06700714T PL06700714T PL1835937T3 PL 1835937 T3 PL1835937 T3 PL 1835937T3 PL 06700714 T PL06700714 T PL 06700714T PL 06700714 T PL06700714 T PL 06700714T PL 1835937 T3 PL1835937 T3 PL 1835937T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- treating viral
- compositions
- viral infection
- receptors
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 abstract 1
- 108010023852 KIR2DL2 Receptors Proteins 0.000 abstract 1
- 102000011419 KIR2DL2 Receptors Human genes 0.000 abstract 1
- 108010023867 KIR2DL3 Receptors Proteins 0.000 abstract 1
- 102000011414 KIR2DL3 Receptors Human genes 0.000 abstract 1
- 108091008877 NK cell receptors Proteins 0.000 abstract 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 102000047041 human KIR2DL1 Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500027 | 2005-01-06 | ||
| PCT/EP2006/050071 WO2006072624A2 (en) | 2005-01-06 | 2006-01-06 | Compositions and methods for treating viral infection |
| EP06700714A EP1835937B1 (en) | 2005-01-06 | 2006-01-06 | Compositions and methods for treating viral infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1835937T3 true PL1835937T3 (pl) | 2012-09-28 |
Family
ID=36593628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06700714T PL1835937T3 (pl) | 2005-01-06 | 2006-01-06 | Kompozycje i sposoby leczenia infekcji wirusowej |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8551483B2 (pl) |
| EP (1) | EP1835937B1 (pl) |
| JP (1) | JP5154949B2 (pl) |
| AT (1) | ATE552852T1 (pl) |
| CY (1) | CY1113182T1 (pl) |
| DK (1) | DK1835937T3 (pl) |
| ES (1) | ES2384466T3 (pl) |
| PL (1) | PL1835937T3 (pl) |
| PT (1) | PT1835937E (pl) |
| SI (1) | SI1835937T1 (pl) |
| WO (1) | WO2006072624A2 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| KR20060079180A (ko) * | 2003-07-02 | 2006-07-05 | 노보 노르디스크 에이/에스 | Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법 |
| WO2006003179A2 (en) * | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US20110280849A1 (en) * | 2010-03-26 | 2011-11-17 | Anthrogenesis Corporation | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
| EA036545B1 (ru) * | 2011-05-25 | 2020-11-20 | Иннейт Фарма, С.А. | Анти-kir антитела для лечения воспалительных заболеваний |
| WO2014189138A1 (ja) * | 2013-05-23 | 2014-11-27 | Ｉｄａｃセラノスティクス株式会社 | 免疫不全ウイルス感染の治療又は予防剤 |
| WO2015035337A1 (en) | 2013-09-06 | 2015-03-12 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS |
| AU2015267051B2 (en) | 2014-05-27 | 2022-03-17 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
| CN106573971A (zh) | 2014-05-27 | 2017-04-19 | 中央研究院 | 抗cd20醣抗体及其用途 |
| CA2950440A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
| CN106714829A (zh) | 2014-05-28 | 2017-05-24 | 中央研究院 | 抗TNF‑α醣抗体及其用途 |
| WO2016031936A1 (ja) | 2014-08-29 | 2016-03-03 | 国立大学法人北海道大学 | Ｋｉｒ２ｄｓ１に対するモノクローナル抗体 |
| WO2017159088A1 (ja) * | 2016-03-16 | 2017-09-21 | 国立大学法人京都大学 | 移植用培養細胞または培養組織の調製方法 |
| US10858431B2 (en) * | 2016-06-30 | 2020-12-08 | Trellis Bioscience, Llc | Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling |
| US10538592B2 (en) | 2016-08-22 | 2020-01-21 | Cho Pharma, Inc. | Antibodies, binding fragments, and methods of use |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| CN109833480B (zh) * | 2019-03-22 | 2021-09-07 | 中国科学院上海巴斯德研究所 | 靶向nk细胞免疫检查点治疗感染性疾病的方法 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
| US5539094A (en) | 1993-11-12 | 1996-07-23 | La Jolla Cancer Research Foundation | DNA encoding Bcl-2-associated proteins |
| US5583034A (en) | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
| US5808028A (en) | 1994-05-24 | 1998-09-15 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clone of a P58 receptor protein and uses thereof |
| MXPA01010891A (es) | 1999-04-28 | 2002-11-07 | Univ Texas | Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf). |
| KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
| KR20060079180A (ko) | 2003-07-02 | 2006-07-05 | 노보 노르디스크 에이/에스 | Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법 |
| US7803376B2 (en) | 2003-07-24 | 2010-09-28 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
-
2006
- 2006-01-06 JP JP2007549894A patent/JP5154949B2/ja not_active Expired - Fee Related
- 2006-01-06 SI SI200631360T patent/SI1835937T1/sl unknown
- 2006-01-06 PT PT06700714T patent/PT1835937E/pt unknown
- 2006-01-06 WO PCT/EP2006/050071 patent/WO2006072624A2/en not_active Ceased
- 2006-01-06 DK DK06700714.6T patent/DK1835937T3/da active
- 2006-01-06 PL PL06700714T patent/PL1835937T3/pl unknown
- 2006-01-06 EP EP06700714A patent/EP1835937B1/en active Active
- 2006-01-06 ES ES06700714T patent/ES2384466T3/es active Active
- 2006-01-06 US US11/813,399 patent/US8551483B2/en not_active Expired - Fee Related
- 2006-01-06 AT AT06700714T patent/ATE552852T1/de active
-
2012
- 2012-06-29 CY CY20121100586T patent/CY1113182T1/el unknown
-
2013
- 2013-10-01 US US14/043,402 patent/US9333255B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006072624A3 (en) | 2006-11-16 |
| CY1113182T1 (el) | 2016-04-13 |
| US20140023646A1 (en) | 2014-01-23 |
| WO2006072624A2 (en) | 2006-07-13 |
| US20090035305A1 (en) | 2009-02-05 |
| JP5154949B2 (ja) | 2013-02-27 |
| DK1835937T3 (da) | 2012-07-23 |
| ES2384466T3 (es) | 2012-07-05 |
| US9333255B2 (en) | 2016-05-10 |
| JP2008526812A (ja) | 2008-07-24 |
| PT1835937E (pt) | 2012-06-25 |
| EP1835937B1 (en) | 2012-04-11 |
| ATE552852T1 (de) | 2012-04-15 |
| SI1835937T1 (sl) | 2012-08-31 |
| EP1835937A2 (en) | 2007-09-26 |
| US8551483B2 (en) | 2013-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113182T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση ιογενους λοιμωξης | |
| NO341586B1 (no) | Fremgangsmåte for valg av et anti-naturlig drepe cellereseptor (NKR) antistoff | |
| DK1578936T3 (da) | Humane anti-IFN-gamma-neutraliserende antistoffer som selektive inhibitorer af IFN-gamma-vejen | |
| BR0212469A (pt) | Método para multiplicação de vìrus em cultura de célula | |
| WO2008085562A3 (en) | Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies | |
| CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
| BRPI0606790A2 (pt) | anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. | |
| WO2004113275A3 (en) | Methods and compositions for treating amyloid-related diseases | |
| IL187321A (en) | Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation | |
| NO20070854L (no) | Humane monoklonale antistoffer mot humant IL-4. | |
| PT2126049E (pt) | Anticorpos contra citomegalovírus humano (hcmv) | |
| NO20064547L (no) | Fremgangsmater for behandling av HIV infeksjon | |
| EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
| CL2024002462A1 (es) | Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 | |
| WO2002092013A3 (en) | Methods for treating liver disease and liver damage with growth hormone and foxm1b | |
| EP2047850A3 (en) | Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | |
| CL2007002370A1 (es) | Conjugado que consta de un anticuerpo anti-ccr5 y uno o mas peptidos antifusogenicos; composicion farmaceutica que lo comprende; metodo de preparacion; y su uso para tratar infecciones virales. | |
| WO2022011110A3 (en) | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection | |
| DE602006019977D1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
| WO2022150654A3 (en) | Antigen-binding polypeptides specific for coronaviruses and uses thereof | |
| WO2006116185A3 (en) | Methods for the treatment of multiple myeloma | |
| ATE389183T1 (de) | Zytokapazität-verfahren | |
| GB0220257D0 (en) | Vaccine | |
| AR055072A1 (es) | Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical | |
| WO2009082594A3 (en) | Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents |